FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210961844> ?p ?o ?g. }

• W4210961844 endingPage "393" @default.
• W4210961844 startingPage "359" @default.
• W4210961844 abstract "Free Access Appendix Antoni Bayés de Luna, Antoni Bayés de Luna Emeritus Professor of Cardiology, Universitat Autònoma de Barcelona Honorary Director, Cardiology Service, Hospital de la Santa Creu i Sant Pau, Barcelona Senior Consultant, Hospital Universitari Quirón, Barcelona, SpainSearch for more papers by this authorAdrian Baranchuk MD FACC FRCPC FCCS, Adrian Baranchuk MD FACC FRCPC FCCS Professor of Medicine, Queen's University, Kingston, Ontario, CanadaSearch for more papers by this author Book Author(s):Antoni Bayés de Luna, Antoni Bayés de Luna Emeritus Professor of Cardiology, Universitat Autònoma de Barcelona Honorary Director, Cardiology Service, Hospital de la Santa Creu i Sant Pau, Barcelona Senior Consultant, Hospital Universitari Quirón, Barcelona, SpainSearch for more papers by this authorAdrian Baranchuk MD FACC FRCPC FCCS, Adrian Baranchuk MD FACC FRCPC FCCS Professor of Medicine, Queen's University, Kingston, Ontario, CanadaSearch for more papers by this author First published: 14 July 2017 https://doi.org/10.1002/9781119212782.app1 AboutPDFPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShareShare a linkShare onFacebookTwitterLinked InRedditWechat References Agelaki M, Pantos C, Korantzopoulos P, I. Comparative antiarrhythmic efficacy of dronedarone and amiodarone during acute MI in rats. Eur J Pharmacol 2007; 564: 150. Alboni P, Botto GL, Baldi N. Outpatients treatment of recent onset atrial fibrillation with “the pill in the pocket” approach. New Engl J Med 2004; 351: 2384. Andersen SS, Hansen LM, Gislason HG, et al. Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a natio wide study. Europace 2009; 11: 886. Andrade JG, Khairy P, Guerra PG, et al. Efficacy and safety of cryoballoon ablation for atrial fibrillation: A systematic review of published studies. Heart Rhythm 2011; 8(9): 1444. Arya A, Silberbauer J, Teichman SL, et al. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace 2009; 11: 458. AVID investigators: Antiarrhythmics Versus Implantable Defibrillators (AVID) – rationale, design, and methods. Am J Cardiol 1995; 75: 470. Bakker PF, Meijburg HW, de Vries JW, et al. Biventricular pacing in end-stage heart failure improves functional capacity and left ventricular function. J Interv Card Electrophysiol 2000; 4: 395. Bakker AL, Nijkerk G, Groenemeijer BE, et al. The Lewis lead: making recognition of P waves easy during wide QRS complex tachycardia. Circulation 2009; 119: e592. Bardy GH, Lee KL, Mark DB, et al. Sudden cardiac death in heart failure trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225. Bardy G, Smith W, Hood M, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363: 36. Bayés de Luna A. Clinical electrocardiography. John Wiley & Sons Ltd, Chichester, 2011. Bayés de Luna A, Serra Grima JR, Oca Navarro F. Electrocardiografia de Holter. Enfoque practico. Editorial Cientifico Medica, Barcelona, 1983. Bayes de Luna A, Fort de Ribot R, Trilla E, et al. Electrocardiographic and vectorcardiographic study of interatrial conduction disturbances with left atrial retrograde activation. J Electrocardiol 1985; 18(1): 1. Bayés de Luna A, Guindo J, Torner P, et al. Value of effort testing and acute drug testing in the evaluation of antiarrhythmic treatment. Eur Heart J 1987(suppl A): 77. Bayés de Luna A, Coumel P, Leclercq JF. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989; 117: 151. Beshai J, Grimm RA, Nagueh SF, et al. Cardioc re-synchronization therapy in heart failure with narrow QRS complexes. New Engl J Med 2007; 357: 2461. Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction and mortality in the 2 years after myocardial infarction. Circulation 1984; 69: 250. Breithardt G, Borgreffe M, Seipel L, et al. Prognostic significance of late ventricular potentials after myocardial infarction. Eur Heart J 1983; 4: 487. Brignole M. Different electrocardiographic manifestations of the cardioinhibitory vasovagal reflex. Europace 2009; 11: 144. Burkhardt D, Natale A. New technologies in atrial fibrillation ablation. Circulation 2009; 120: 1533. Buxton AE. Prevention of sudden death in patients with coronary artery disease: the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis 1993; 36: 215. Cakulev I, Efimov IR, Waldo AL. Cardioversion: past, present, and future. Circulation 2009; 120: 1623. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369. Castel MA, Magnani S, Mont L, et al. Survival in New York Heart Association class IV heart failure patients treated with cardiac resynchronization therapy compared with patients on optimal pharmacologial treatment. Europace 2010; 12: 1136. Cazeau S, Ritter P, Bakdach S, et al. Four chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994; 17: 1974. Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608. Chung ES, Katra RP, Ghio S, et al. Cardiac resynchronization therapy may benefit patients with left ventricular ejection fraction >35%: a PROSPECT trial substudy. Eur J Heart Fail 2010a; 12: 581. Chung MK, Szymkiewicz SJ, Shao M, et al. Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. J Am Coll Cardiol 2010b; 56: 194. Connolly SJ, Gent M, Roberts RS, et al. Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101: 1297. Cook GE, Sasich LD, Sukkari SR. Atrial fibrillation. DIONYSOS study comparing dronedarone with amiodarone. Br Med J 2010; 340: c285. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; 365(24): 2268. Coons JC, Klauger KM, Seybert AL, Sokos GG. Worsening of heart failure in the setting of dronedarone initiation. Ann Pharmacother 2010; 44: 1496. Davy J, Herold M, Hoglund C, et al. Dronadorone for the control of ventricular rate in permanent atrial fibrillation: The ERATO study. Am Heart J 2008; 156: 257e1. De Ambroggi L, Negroni MS, Monza E, et al. Dispersion of ventricular repolarization in the long QT syndrome. Am J Cardiol 1991; 68: 614. Della Bella P, Pappalardo A, Riva S, et al. Non-contact mapping to guide catheter ablation of untolerated ventricular tachycardia. Eur Heart J 2002; 23: 742. Disertori M, Latini R, Barlera S, et al. GISSI-AF Investigators Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991; 324: 781. Eitel C, Hindricks G, Sommer P, et al. Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 2010; 7: 157. Fink A., Duray G., Hohnlosser S. A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone. Europace 2011; 13(2): 284. Friedman PA, Asirvatham SJ, Grice S, et al. Noncontact mapping to guide ablation of right ventricular outflow tract tachycardia. J Am Coll Cardiol 2002; 39: 1808. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011; 57(11): e101. Gasparini M, Lunati M, Santini M, et al. Long-term survival in patients treated with cardiac resynchronization therapy: a 3-year follow-up study from the InSync/InSync ICD Italian Registry. Pacing Clin Electrophysiol 2006; 29(Suppl 2): S2. Gasparini M, Menozzi C, Proclemer A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischaemic cardiomyopathy implanted for primary prevention: the RELEVANT [Role of long dEtection window programming in patients with LEft VentriculAr dysfunction, Non-ischemic eTiology in primary prevention treated with a biventricular ICD] study. Eur Heart J 2009; 30: 2758. Gomes JA, Winters SL, Steward D, Horowitz S, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction. J Am Coll Cardiol 1987; 10: 349. Gradaus R, Stuckenborg V, Loher A., et al. Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy. Heart 2008; 94: 1026. Haïssaguerre M, Jais P, Shah DC et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary veins foci. Circulation 2000; 101: 1409. Hausenloy DJ, Arhi C, Chandra N et al. Blood pressure oscillations during tilt testing as a predictive marker of vasovagal syncope. Europace 2009; 11: 1696. Hohnloser SH, Crijns HJ, van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668. Holmes DR, Reddy Y, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374: 534. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 2014; 64: 1. Hubley-Kozey CL, Mitchell LB, Gardner MJ, et al. Spatial features in body-surface potential maps can identify patients with a history of sustained ventricular tachycardia. Circulation 1995; 92: 1825. Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children. Am J Cardiol 1998; 81: 1121. Janse MJ, Malik M, Camm AJ, et al. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial). Eur Heart J 1998; 19: 85. Kadish A, Hauck J, Pederson B, et al. Mapping of atrial activation with a noncontact, multielectrode catheter in dogs. Circulation 1999; 99: 1906. Khairy P, Dubuc M. Transcatheter cryoablation part I: preclinical experience. Pacing Clin Electrophysiol 2008; 31: 112. Korhonen P, Husa T, Konttila T, et al. Complex T-wave morphology in body surface potential mapping in prediction of arrhythmic events in patients with acute myocardial infarction and cardiac dysfunction. Europace 2009; 11: 514. Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial. Conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104: 46. Krahn AD, Klein GJ, Yee R, Skanes AC. The use of monitoring strategies in patients with unexplained syncope – role of the external and implantable loop recorder. Clin Auton Res 2004; 14(Suppl 1): 55. Krishnamoorthy S, Lip G. How is safe the antiarrhythmic drug therapy in atrial fibrillation? PACE 2009; 11: 837. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. J Am Coll Cardiol 1987; 9: 531. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102: 748. Kuck KH, Brugada J, Fürnkranz A, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016; 374(23): 2235. Kumar S, Sivagangabalan G, Zaman S, et al. Electrophysiology-guided defibrillator implantation early after ST-elevation myocardial infarction. Heart Rhythm 2010; 7: 1589. Lin Y-J, Tsao H-M, Chang S-L, et al. Prognostic implications of the high-sensitive C-reactive protein in the catheter ablation of atrial fibrillation. Am J Cardiol 2010; 105: 495. Marchant M, Heist E, McMarty D, et al. Impact of segmented left ventricle lead position on CRT outcomes. Heart Rhythm 2010; 7: 639. Mazzini MJ, Monahan KM. Pharmacotherapy for atrial arrhythmias: present and future. Heart Rhythm 2008; 5(6 Suppl): S26. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implantable automatic defibrillator in human beings. N Engl J Med 1980; 303: 322. Mohajer K, Fregeau B, Garg V, et al. Management of atrial fibrillation by Canadian electrophysiologists after early termination of the PALLAS study. Can J Cardiol 2013; 29(1):131. e1- 2. Moss AJ. MADIT-II and implications for noninvasive electrophysiologic testing. Ann Noninvasive Electrocardiol 2002; 7: 179. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 335: 1933. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361: 1329. Myerburg R, Reddy V, Castellanos A. Indications for implantable cardioverter-defibrillators based on evidence and judgment. J Am Coll Cardiol 2009; 54: 747. Nattel S. Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance. Drugs 1991; 41: 672. Nattel S. G-protein signaling and arrhythmogenic atrial remodeling: relevance to novel therapeutic targets in atrial fibrillation. Heart Rhythm 2009; 6: 85. Oakes RS, Badger TJ, Kholmovski G, et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009; 119: 1758. Oyenuga O, Hara H, Tanaka H, et al. Usefulness of echocardiographic dyssynchrony in patients with borderline QRS duration to assist with selection for cardiac resynchronization therapy. JACC Cardiovasc Imaging 2010; 3: 132. Pappone C, Santinelli V. Ablation of atrial fibrillation. Curr Cardiol Rep 2006; 8: 343. Pérez Riera AR, Uchida AH, Filho CF, et al. Significance of vectorcardiogram in the cardiological diagnosis of the 21st century. Clin Cardiol 2007; 30(7): 319. Postema PG, van Dessel PF, Kors JA, et al. Local depolarization abnormalities are the dominant pathophysiologic mechanism for type 1 electrocardiogram in Brugada syndrome a study of electrocardiograms, vectorcardiograms, and body surface potential maps during ajmaline provocation. J Am Coll Cardiol 2010; 55: 789. Pouleur A, Barkoudah E, Uno H, et al. Pathogenesis of sudden death in a clinical trial of patients post myocardial infarction with left ventricular dysfunction. Circulation 2010; 122: 597. Reddy VY, Exner DV, Cantillon DJ, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med 2015; 373: 1125. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014; 312: 1988. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. Circulation. 2015; 132(10): 907. Reynolds D, Duray GZ, Omar R, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med 2016; 374: 533. Ricci RP, Morichelli L, Santini M. Home monitoring remote control of pacemaker and implantable cardioverter defibrillator patients in clinical practice: impact on medical management and health-care resource utilization. Europace 2008; 10: 164. Ricci RP, Morichelli L, Santini M. Remote control of implanted devices through home monitoring technology improves detection and clinical management of atrial fibrillation. Europace 2009; 11: 54. Roden DM. Cardiovascular pharmacogenomics. Circulation 2003; 108: 3071. Saba S, Volosin K, Yee R, et al. Combined atrial and ventricular antitachycardia pacing as a novel method of rhythm discrimination: the dynamic discrimination download study. Circulation 2010; 121: 487. Schwartz PJ, Zaza A. The Sicilian Gambit revisited – theory and practice. Eur Heart J 1992; 13(Suppl F): 23. Shaaraoui M, Freudenberger R, Levin V, et al. Suppression of ventricular tachycardia with dronedarone: a case report. J Cardiov Electrophysiol 2011; 22(2): 201. Sheldon R. Syncope diagnostic scores. Prog Cardiovasc Dis 2013; 55(4): 390. Singh D, Cingoleni E, Diamond G, et al. Dronadorone for atrial fibrillation. J Am Coll Cardiol 2010; 55: 1569. Stecker E. Is there new hope for sudden cardiac death prevention early after MI. Heart Rhythm 2010; 7: 1598. Stockburger M, Krebs A, Nitardy A, et al. Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death. Pacing Clin Electrophysiol 2009; 32(Suppl 1): S16. Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. Circulation 2006 ; 113(2): 316. Sutton R, Bloomfield DM. Indications, methodology, and classification of results of tilt-table testing. Am J Cardiol 1999; 84: 10Q. Sweeney MO, van Bommel RJ, Schalij MJ, et al. Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. Circulation 2010; 121: 626. Tereshchenko LG, Faddis MN, Fetics BJ, et al. Transient local injury current in right ventricular electrogram after implantable cardioverter-defibrillator shock predicts heart failure progression. J Am Coll Cardiol 2009; 54: 822. Theroux P, Waters DD, Halphen C, et al. Prognostic value of exercise test soon after myocardial infarction. N Engl J Med 1979; 301: 341. Tomoda H. Valsartan and recurrent atrial fibrillation. N Engl J Med 2009; 361: 532. Top-Pedersen C, Pedersen OD, Køber L. Antiarrhythmic drugs: safety first. J Am Coll Cardiol 2010; 55(15): 1577. Tung R, Boyle NG, Shivkumar K. Catheter ablation of ventricular tachycardia. Circulation 2010; 122: e389. Tzikas A, Shakir S, Gafoor S, et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicenter experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016; 11: 1170. Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. Heart Rhythm 2012; 9: 728. Vardas PE, Auricchio A, Blanc JJ, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J 2007; 28: 2256. Vardas PE. White Book of electrophysiology in Europe. Publication of the European Society of Cardiology 2010. Vaughan-Williams EM. Review of classification of antiarrhythmic agents. In: A Bayés de Luna, J Cosin, eds, Diagnosis and treatment ofcardiac arrhythnias, Pergamon Press, New York, 1980, p. 125. Vereckei A, Duray G, Szénási G, et al. New algorithm using only lead a VR for differential diagnosis of wide QRS complex tachycardia. Heart Rhythm 2008; 5: 89. Verma A, Mantovan R, Macle L, et al. Substrate and trigger ablation for reduction of atrial fibrillation (STAR AF): a randomized, multicentre, international trial. Eur Heart J 2010; 31: 1344. Zareba W. Inappropriate implantable cardioverter defibrillator therapy. Cardiology J 2009; 16: 391. Zhang F, Yang B, Chen H, et al. Noncontact mapping to guide ablation of right ventricular outflow tract arrhythmias. Heart Rhythm 2013; 10: 1895. Zimetbaum PJ. Dronedarone for atrial fibrillation – an odyssey. N Engl J Med 2009; 360: 1811. Clinical Arrhythmology, Second Edition ReferencesRelatedInformation" @default.
• W4210961844 created "2022-02-13" @default.
• W4210961844 date "2017-07-14" @default.
• W4210961844 modified "2023-10-14" @default.
• W4210961844 title "Appendix" @default.
• W4210961844 cites W101577944 @default.
• W4210961844 cites W1252671405 @default.
• W4210961844 cites W132631509 @default.
• W4210961844 cites W1491897499 @default.
• W4210961844 cites W1587426953 @default.
• W4210961844 cites W1625841550 @default.
• W4210961844 cites W1778612245 @default.
• W4210961844 cites W1969065299 @default.
• W4210961844 cites W1970891004 @default.
• W4210961844 cites W1971352825 @default.
• W4210961844 cites W1974710452 @default.
• W4210961844 cites W1977036718 @default.
• W4210961844 cites W1977890237 @default.
• W4210961844 cites W1981964073 @default.
• W4210961844 cites W1985799453 @default.
• W4210961844 cites W1989416511 @default.
• W4210961844 cites W1998363799 @default.
• W4210961844 cites W1999251033 @default.
• W4210961844 cites W2002374666 @default.
• W4210961844 cites W2004675361 @default.
• W4210961844 cites W2009933853 @default.
• W4210961844 cites W2011106890 @default.
• W4210961844 cites W2012097209 @default.
• W4210961844 cites W2013784865 @default.
• W4210961844 cites W2016759882 @default.
• W4210961844 cites W2018173278 @default.
• W4210961844 cites W2021716008 @default.
• W4210961844 cites W2025876819 @default.
• W4210961844 cites W2026137049 @default.
• W4210961844 cites W2028534817 @default.
• W4210961844 cites W2029508724 @default.
• W4210961844 cites W2032870992 @default.
• W4210961844 cites W2042591478 @default.
• W4210961844 cites W2043940370 @default.
• W4210961844 cites W2045077132 @default.
• W4210961844 cites W2051894387 @default.
• W4210961844 cites W2053586202 @default.
• W4210961844 cites W2056668772 @default.
• W4210961844 cites W2060740808 @default.
• W4210961844 cites W2062570343 @default.
• W4210961844 cites W2063376725 @default.
• W4210961844 cites W2066830109 @default.
• W4210961844 cites W2075142560 @default.
• W4210961844 cites W2075175982 @default.
• W4210961844 cites W2078722399 @default.
• W4210961844 cites W2085822631 @default.
• W4210961844 cites W2088825357 @default.
• W4210961844 cites W2088877169 @default.
• W4210961844 cites W2094892482 @default.
• W4210961844 cites W2096958997 @default.
• W4210961844 cites W2097785381 @default.
• W4210961844 cites W2100056258 @default.
• W4210961844 cites W2101305930 @default.
• W4210961844 cites W2102041852 @default.
• W4210961844 cites W2103958748 @default.
• W4210961844 cites W2105496456 @default.
• W4210961844 cites W2105894476 @default.
• W4210961844 cites W2106251839 @default.
• W4210961844 cites W2107050765 @default.
• W4210961844 cites W2109227928 @default.
• W4210961844 cites W2109573614 @default.
• W4210961844 cites W2112438292 @default.
• W4210961844 cites W2112970567 @default.
• W4210961844 cites W2117848800 @default.
• W4210961844 cites W2122519468 @default.
• W4210961844 cites W2124646419 @default.
• W4210961844 cites W2127477186 @default.
• W4210961844 cites W2133639526 @default.
• W4210961844 cites W2133682664 @default.
• W4210961844 cites W2134276162 @default.
• W4210961844 cites W2135161353 @default.
• W4210961844 cites W2136071898 @default.
• W4210961844 cites W2136874402 @default.
• W4210961844 cites W2139305230 @default.
• W4210961844 cites W2144202315 @default.
• W4210961844 cites W2144842018 @default.
• W4210961844 cites W2146521529 @default.
• W4210961844 cites W2148632106 @default.
• W4210961844 cites W2151925690 @default.
• W4210961844 cites W2156179058 @default.
• W4210961844 cites W2158967092 @default.
• W4210961844 cites W2159588890 @default.
• W4210961844 cites W2160313515 @default.
• W4210961844 cites W2161696103 @default.
• W4210961844 cites W2163247235 @default.
• W4210961844 cites W2164861810 @default.
• W4210961844 cites W2166888055 @default.
• W4210961844 cites W2172227589 @default.
• W4210961844 cites W2178696728 @default.
• W4210961844 cites W2209049165 @default.
• W4210961844 cites W2229873756 @default.
• W4210961844 cites W2234489653 @default.
• W4210961844 cites W2243962981 @default.

• next